Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the sale, the chief executive officer now owns 990,392 shares of the company’s stock, valued at approximately $20,629,865.36. This represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock traded up $0.61 during mid-day trading on Wednesday, hitting $20.89. 144,067 shares of the stock were exchanged, compared to its average volume of 269,755. The company has a market capitalization of $1.02 billion, a P/E ratio of -10.99 and a beta of 1.04. The company has a 50-day simple moving average of $21.45 and a 200 day simple moving average of $23.80. Enliven Therapeutics, Inc. has a 12 month low of $14.50 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. Analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, BTIG Research initiated coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $38.25.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ELVN. Tower Research Capital LLC TRC grew its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at $97,000. BNP Paribas Financial Markets purchased a new position in Enliven Therapeutics in the fourth quarter worth $112,000. ExodusPoint Capital Management LP bought a new stake in Enliven Therapeutics in the fourth quarter worth $200,000. Finally, Brevan Howard Capital Management LP bought a new stake in Enliven Therapeutics in the fourth quarter worth $228,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.